Three versus one year of adjuvant imatinib for high-risk gastrointestinal stromal tumor (GIST): Survival analysis of a randomized trial after 10 years of follow-up.
Journal title abbreviation:
J Clin Oncol
Year:
2020
Journal volume:
38 Suppl S
Journal issue:
15
Print-ISSN:
0732-183X
TUM Institution:
III. Medizinische Klinik und Poliklinik (Hämatologie / Onkologie)